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Herman Wong, MBBS,* Anthony T.C. Chan, MD,* Winnie Yeo, MD,*
Anthony P.C. Yim, MD, FCCP,‡ Karen Chak, RN,* Yolanda Lee, MBBS, and Kwok-Chi Lam, MBBS*
Background: Sequential administration of platinum-based doublet
therapy and then a taxane may reduce the risk of drug resistance and,
therefore, improve treatment outcome. This study was designed to
evaluate the efficacy and tolerability of sequential administration of
irinotecan and cisplatin and then docetaxel in patients with advanced
non-small cell lung cancer (NSCLC).
Methods: Eligible patients received irinotecan in 60-mg/m2 infu-
sions for 30 to 60 minutes on days 1, 8, and 15, and cisplatin in
75-mg/m2 infusions for 60 minutes on day 1 every 28 days for four
cycles (IC). Regardless of the response, patients received up to four
cycles of sequential docetaxel in 75-mg/m2 infusions for 60 minutes.
Results: Forty-six patients with histologically confirmed chemo-
therapy-naı¨ve stage IIIB or IV NSCLC were enrolled, of whom 42
were evaluable. The response rate at completion of chemotherapy
with IC was 45.2% (95% confidence interval [CI]: 30.2%–60.3%).
Five patients had improvement of disease status during sequential
docetaxel, and seven patients had disease progression. Progression-
free survival was 8.0 months (95% CI: 5.4–9.9 months), and the
overall median survival was 14.6 months (95% CI: 9.8–17.9
months). The 1-, 2-, and 3-year survival rates were 54.3%, 22.6%,
and 12.1%, respectively. The incidence of severe (CTC V2 grade
3) neutropenia during IC was 23.9% compared with 95.7% for
sequential docetaxel (p  0.0001).
Conclusion: Sequential administration of IC and then docetaxel is
feasible and is associated with a prolonged progression-free sur-
vival, but the current data do not confirm an improvement in
treatment outcome by the sequential approach.
Key Words: Carcinoma, Non-small cell lung, Docetaxel, Drug
resistance, Drug therapy, Combination, Irinotecan.
(J Thorac Oncol. 2007;2: 838–844)
Platinum-based combination chemotherapy prolongs sur-vival of patients with advanced stage non-small cell lung
cancer (NSCLC).1 The combination of platinum with cyto-
toxic drugs such as gemcitabine, taxanes, or vinorelbine have
become the standard first-line therapy for NSCLC.2–4 Com-
parison studies have confirmed the efficacy of these doublet
therapies to be similar, as are the novel modifications such as
triplet therapy and non–platinum-based doublet therapy.5–9
Sequential administration of a taxane after platinum-
based doublet therapy is scientifically sound and potentially
less toxic than platinum-based triplet therapy. Mathematical
models suggest that sequential administration of drugs with
different mechanisms of action could be superior to concur-
rent administration.10,11 An updated, computerized model of
chemotherapy drug scheduling also suggested that sequential
administration could optimize outcomes.12 Clinically, it is
known that docetaxel could be used for salvage for patients
with platinum-resistant NSCLC.13 The single-drug regimen
attained a tumor response rate of 7.1% and improved median
survival to 7.0 months. Thus, sequential administration of a
taxane immediately after first-line chemotherapy may be asso-
ciated with improved treatment outcome. The cytotoxic proper-
ties of the taxanes depends in part on an intact p53 pathway, so
the sequential use of a taxane after platinum-based chemother-
apy could minimize the risk for drug resistance.14,15
Irinotecan (CPT-11, Campto) is a water-soluble camp-
tothecin derivative that inhibits topoisomerase I, the intranu-
clear enzyme that relieves torsion in DNA during replication.
Phase II studies of a combination of irinotecan and cisplatin
(IC) have demonstrated efficacy in advanced NSCLC.16–19
The tumor response rate ranged from 25.0% to 37.8%, and
the median survival was 7.4 to 10.0 months. Diarrhea was
common but was well tolerated with the aid of a simple
antidiarrhea agent. A comparative study of IC versus cisplatin
and vindesine showed that IC was associated with a higher
tumor response rate and similar median survival.20 The com-
bination was not included in the major American study
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(ECOG 1594) that compared the efficacy of four platinum-
based first-line regimens, but a Japanese comparative study
has confirmed that this combination achieved results similar
to those for cisplatin combined with paclitaxel, docetaxel, or
gemcitabine.21 IC is recognized as a standard regimen for
advanced NSCLC.
Although maintenance therapy with single-agent third-
generation cytotoxic drugs after platinum-based doublet is
not capable of improving overall survival,22,23 use of alternate
agent as sequential therapy has not been thoroughly studied.
We hypothesized that sequential administration of IC and
then docetaxel may attain greater efficacy without added
toxicity. We chose irinotecan and cisplatin for their different
mechanisms of action and nonoverlapping toxicity. Do-
cetaxel is a standard second-line therapy for patients who had
failed a platinum-based regimen.13 This phase II study was
conducted to evaluate the efficacy and tolerability of sequen-
tial administration of IC and then docetaxel in patients with
advanced NSCLC.
METHODS
Eligibility
Patients aged between 18 and 70 years, with Eastern
Cooperative Oncology Group performance scale 2 and
stage IIIb or IV histologically/cytologically proven NSCLC
were eligible for this study. All patients were chemotherapy
naı¨ve and had measurable disease at one or more disease sites
measured by computed tomography (CT). Prior irradiation
for NSCLC was permitted, but the measurable or evaluable
nonmeasurable disease had to be completely outside the
radiation portal. All enrolled patients were capable of under-
standing the diagnosis and the nature of the trial, and signed
the consent form. Patients with symptomatic central nervous
system metastases, concurrent malignancy, uncontrolled hy-
percalcemia, inflammatory bowel disease, and life-threaten-
ing medical conditions were excluded. Patients with impaired
renal and liver functions, and women who were pregnant or
lactating were also excluded. The minimal liver function
requirement was total bilirubin no more than twice the upper
limit of normal (ULN); aspartate aminotransferase or alanine
aminotransferase no more than three times ULN; and alkaline
phosphatase no more than three times ULN without liver or
bone metastasis, or no more than five times ULN. The serum
creatinine requirement was 140 M, and creatinine clear-
ance was 60 ml/min.
Study Design
This was a single-arm, open-label, single-center phase
II study. The primary objective was to assess the tumor
response rate after sequential administration of IC and then
single-agent docetaxel for the treatment of advanced NSCLC.
The secondary objectives were time to progression (TTP),
median survival, safety, and change in quality of life (QOL)
during treatment. The additional benefit of docetaxel for
reducing tumor size in patients with stable disease or a partial
response to IC and its role as salvage therapy for patients with
resistant disease was also studied. The study was conducted
according to the Principles of Good Clinical Practice. The
protocol and consent form (in both Chinese and English)
were approved by the joint research ethics committee of the
Prince of Wales Hospital and The Chinese University of
Hong Kong.
Treatment
Irinotecan (60 mg/m2; 250-ml normal saline infusion)
was administered for 30 to 60 minutes on days 1, 8, and 15,
every 28 days. Cisplatin was given at the standard dosage of
75 mg/m2 in a 250-ml normal saline infusion for 1 hour on
day 15. Routine antiemetics of metoclopramide (10 mg) and
dexamethasone (10 mg) were administered intravenously
before irinotecan infusion. Ondansetron and dexamethasone
were given on day 15 before cisplatin infusion. Docetaxel (75
mg/m2, in 250 ml of normal saline) was infused for 60
minutes on day 1 of a 3-week cycle. Patients received
prophylactic dexamethasone and antiemetics.
Patients who attained a partial response or stable dis-
ease with IC completed four cycles before switching to
docetaxel. If the disease progressed or toxicity became unac-
ceptable to the patient or investigator, the patient switched to
docetaxel before completion of four cycles of IC. All patients
received a maximum of four cycles of docetaxel. If the
sequential regimen under study failed, the investigator had
the discretion of prescribing other salvage therapy.
The IC dose was modified according to hematologic or
renal toxicity. Irinotecan infusion was delayed if the neutro-
phil count was less than 500/mm2 on days 8 or 15. If
neutropenia was persistent after 7 days, the dose was not
given. If the neutrophil count was less than 1000/mm3 and the
platelet count was 75,000/mm2 on day 1, the subsequent
cycle was delayed for 7 to 14 days. If the neutrophil count
was less than 1000/mm3 and the platelet count was less
75,000/mm2 on day 15, the cisplatin infusion was delayed for
7 days. If neutropenia was persistent after 7 days, the dose
was not given. Serum creatinine was monitored before each
cisplatin infusion, and the dose was reduced by 50% if
creatinine clearance was between 40 and 60 ml/min. If
creatinine clearance was less than 40 ml/min, the cisplatin
infusion was discontinued.
Treatment was discontinued in the presence of disease
progression, intolerable toxicity, concurrent serious medical
conditions, or completion of eight cycles of therapy. Radical
radiation was offered to patients with local regional stage IIIb
disease after completion of chemotherapy and confirmation
of tumor response status. Palliative radiation was given for
symptomatic disease. The treatment field involved the site of
measurable disease only after discontinuation of the study
treatment.
Assessment
At enrollment, all patients underwent complete medical
history and physical examination, laboratory assessment, chest
radiograph, and CT scan of the thorax and upper abdomen.
Laboratory assessment included complete blood count (CBC),
renal function tests, liver function tests, serum calcium, coagu-
lation profile, blood glucose, and 24-hour urine collection for
creatinine clearance and total protein. Bone scan and CT scan of
the brain were indicated for symptomatic patients.
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Hematologic toxicity was monitored by CBC on days
1, 8, 15, and 22 of each cycle of IC and on days 1 and 8 of
each cycle of docetaxel. Laboratory assessments, with the
exception of blood glucose, serum calcium, and coagulation
profile, were repeated on day 1 of each cycle of chemother-
apy. Chest radiograph was repeated monthly. Imaging of the
measurable tumor by CT scan was repeated every two cycles.
Toxicity was graded according to the National Cancer Insti-
tute Common Toxicity Criteria version 2.0 (NCI CTC-V2),
and tumor response was defined by the World Health Orga-
nization criteria.24 All radiological imaging was reviewed by
a designated radiologist and investigator but not by an inde-
pendent panel. Time to progression was defined as the time
from randomization to the date of documentation of disease
progression. Overall survival was measured from the date of
randomization to the date of death.
QOL Assessment
QOL was measured by the validated Chinese transla-
tion of the European Organization of Research and Treatment
of Cancer core questions on the Quality of Life Question-
naire, version 2 (QLQ-C30).25,26 Patients completed this
self-administered questionnaire on day 1 of each cycle and at
monthly follow-up visits until the date of confirmed tumor
progression.
Statistical Methods
The primary endpoint of the study was to investigate
the tumor response rate of the sequential regimen of IC
followed by docetaxel. Simon’s optimal two-stage design
was used for estimation of sample size. Assuming 30%
responders for the null hypothesis versus 50% responders for
the alternative hypothesis, 46 patients were needed for 80%
power using a 5% level test. Fifteen evaluable patients were
enrolled in the first stage, and if there were fewer than five
partial responses, the study would be stopped. Otherwise,
accrual would continue until the target sample size of 46
evaluable patients was reached.
Intent-to-treat analyses were performed for all enrolled
patients. Overall survival and TTP were estimated using the
Kaplan–Meier method. The log–rank test was used for com-
parison of time-to-event endpoints, and the chi-square
method was used for testing differences in toxicity and
response rates. Frequency of toxicity was tabulated according
to the most severe toxicity during each cycle of chemother-
apy. The change in mean scores of QOL domains and
symptoms was compared with the baseline score using the
Wilcoxon rank–sum test.
RESULTS
Patient Characteristics
Forty-six patients were enrolled between January 2002
and November 2003. Patients’ characteristics are summarized
in Table 1. A high proportion of patients with stage IIIB
disease were eligible for this study (43.4%). Only 15.2% of
patients had the histologic subtype of squamous cell carci-
noma. The remaining patients had adenocarcinoma or
NSCLC without exact subtyping. All 46 patients received at
least one cycle of chemotherapy, but four patients were
discontinued from the study before tumor evaluation. One
patient died from non–treatment-related complications, one
patient required urgent radiotherapy for superior vena cava
obstruction, one patient declined further therapy, and one
patient refused platinum-based treatment and requested to
switch to docetaxel after one cycle of IC. Forty-two
patients were evaluable for tumor response, but all 46
patients were analyzed for survival according to the inten-
tion-to-treat analysis.
Treatment
One hundred sixty-one cycles of IC were given to 46
patients, with a median of four cycles per patient. Forty-two
of the 46 patients were evaluable and eligible to continue with
sequential administration of docetaxel, five of whom dropped
out for reasons of patient refusal (three patients) and toxicity
(two patients). The remaining 37 patients received 134 cycles
of single-agent docetaxel, with a median of four cycles per
patient. Radical radiotherapy was given to four patients with
stage IIIb disease. Other patients with stage IIIb disease did
not receive radical radiotherapy for the reason of pleural
effusion,6 contralateral supraclavicular lymph node metasta-
sis,7 poor lung function,1 and refusal.1 Palliative radiation
was given to 18 patients for symptom control at various
extrathoracic sites, including bone, axilla, brain, and supra-
clavicular lymph nodes. Twenty-three patients received sal-
vage chemotherapy, including gemcitabine, pemetrexed, or
vinorelbine, and eight patients received gefitinib as second-
or third-line therapy. In addition, 14 patients used Chinese
herbal medicine as the only salvage/supportive therapy.
Tumor Response and Survival
Treatment outcomes are summarized in Table 2. None
of the patients achieved a complete response. The tumor
TABLE 1. Patient Characteristics
No. of patients 46
Median age in years (range) 55 (32–70)
Gender, no. (%)
Male 39 (84.8)
Female 7 (15.2)
Stage, no. (%)
IIIB 20 (43.4)
IV 26 (56.5)
Histology, no. (%)
Adenocarcinoma 20 (43.4)
Squamous cell carcinoma 7 (15.2)
Non-small cell lung cancer 15 (32.6)
Other (large-cell carcinoma, bronchoaveloar carcinoma) 4 (8.7)
Performance status (ECOG), no. (%)
0 7 (15.2)
1 37 (80.4)
2 2 (4.4)
Prior surgery
Yes 4 (8.7)
No 42 (91.3)
ECOG, Eastern Cooperative Oncology Group.
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response rate of 42 evaluable patients at completion of IC was
47.6% (95% confidence interval [CI]: 32.5%–62.7%). Four
patients with partial response and three patients with stable
disease with IC progressed during sequential therapy with
docetaxel, whereas five patients had improvement of tumor
response status. The tumor response rate at completion of all
treatment was 45.2% (95% CI: 30.2%–60.3%). Median fol-
low-up was 46.4 months (95% CI: 42.6–52.6 months.) Pro-
gression-free survival using the first day of IC infusion as the
reference point was 8.04 months (95% CI: 5.4–9.9 months).
Using the first day of docetaxel infusion as a reference point,
the progression-free survival was 6.1 months (95% CI: 4.7–
6.5 months). The overall median survival was 14.6 months
(95% CI: 9.8–17.9 months); Figure 1. The 1-, 2-, and 3-year
survival rates were 54.3%, 22.6%, and 12.1%, respectively.
Toxicity
Hematologic and nonhematologic toxicities are sum-
marized in Tables 3 and 4, respectively. IC was well toler-
ated. Only 23.9% of patients experienced severe (CTC V2
grade 3) neutropenia during IC administration. Sequential
administration of docetaxel was more myelotoxic than IC.
The grade 3/4 neutropenia rate of 95.7% was significantly
higher than that of IC (p  0.001). Four patients required
treatment deferral, and seven patients experienced neutro-
penic fever during docetaxel administration compared with
none during IC administration. Nonhematologic toxicities
were relatively mild and well tolerated with both regimens.
Anorexia, nausea, and vomiting were more common with the
cisplatin-containing regimen (p  0.02, 0.007, and 0.002,
respectively). Fatigue was more common with the taxane
regimen, but the difference was not statistically significant.
QOL
The changes in QOL from baseline during IC admin-
istration and from the last day of IC during docetaxel admin-
istration were documented. Tables 5 and 6 summarize the
domains with significant changes (p  0.05). Forty-three
TABLE 3. Hematologic Toxicity
CTC-V2 >
Grade 3 Toxicity
IC (n  46)
No. (%) of
Patients
Docetaxel (n  37)
No. (%) of
Patients p
Anemia 2 (4.4) 2 (5.4) 0.05
Leukopenia 7 (15.2) 26 (70.3) 0.001
Neutropenia 11 (23.9) 35 (95.7) 0.001
Thrombocytopenia 3 (6.5) 5 (13.5) 0.28
CTC, common toxicity criteria; IC, irinotecan and cisplatin combination.
TABLE 4. Nonhematologic Toxicity
CTC-V2 >
Grade 2 Toxicity
IC (n  46)
No. (%) of
Patients
Docetaxel (n  37)
No. (%) of
Patients p
Diarrhea 3 (6.5) 1 (2.7) 0.42
Fatigue 10 (21.7) 14 (37.8) 0.11
Anorexia 15 (32.6) 4 (10.8) 0.02
Nausea 15 (32.6) 3 (8.1) 0.007
Vomiting 17 (36.9) 1 (2.7) 0.002
Skin 1 (2.2) 1 (2.7) 0.87
Weight loss 2 (4.3) 1 (2.7) 0.69
CTC, common toxicity criteria; IC, irinotecan and cisplatin combination.
TABLE 2. Tumor Response to Sequential Chemotherapy with Irinotecan and Cisplatin (IC), Followed by
Docetaxel
Tumor Response After
IC (n  42)
No. (%) of Patients
Change in Tumor Response
After Docetaxel
No. (%) of Patients
Tumor Response at End
of Treatment
No. (%) of Patients
Complete response 0 (0) 0 (0) 0 (0)
Partial response 20 (47.6) Remain in PR 16 (80.0) 19 (45.2)
Progressed 4 (20.0)
Stable disease 11 (26.2) Attain PR 2 (18.2) 8 (19.1)
Remain SD 6 (54.5)
Progressed 3 (27.3)
Progressive disease 11 (26.2) Attain PR 1 (9.1) 15 (35.7)
Attain SD2 (18.2)
Remain PD 8 (72.7)
PR, partial response; SD, stable disease; PD, progressive disease, IC, irinotecan and cisplatin.
FIGURE 1. Overall survival of patients who received se-
quential chemotherapy with irinotecan and cisplatin and
then docetaxel.
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patients participated in the QOL assessment, and the compli-
ance rate for completion was high for all cycles (100%,
81.45%, 81.4%, and 81.4% for cycles 1, 2, 3, and 4, respec-
tively). The compliance rates for QOL assessment for do-
cetaxel cycles 1 to 4 were 97.3%, 97.3%, 91.1%, and 75.7%,
respectively. Patients noticed significant improvement from
baseline in the physical, role, and cognitive domains during
IC administration, and the benefits were sustained during
docetaxel administration. The change in QOL score was
persistently significant in IC cycles 1 to 4, and the change
from the end of IC administration through four cycles of
docetaxel was minimal. Nevertheless, there was a substantial
increase in treatment-related symptoms of anorexia, nausea,
and diarrhea. The problem of nausea and anorexia started
from cycle 1 of IC administration, whereas diarrhea became
significant only at cycle 3. All of these symptoms improved
when patients were switched to docetaxel. There was a
significant increase of symptoms suggestive of peripheral
neuropathy towards the last two cycles of docetaxel.
DISCUSSION
Sequential administration of platinum-based doublet
therapy and then a taxane is theoretically and biologically
sound. The rationale for sequential chemotherapy includes
the activity of a taxane in platinum-resistant NSCLC and
maximization of drug delivery.15,27 In this phase II study, a
high tumor response rate of 47.6% was observed with IC
(95% CI: 32.5%–62.7%). Nevertheless, administration of
sequential docetaxel did not increase the overall response
rate. Four of 20 patients (20%) who attained a partial re-
sponse with IC progressed with docetaxel, and only 3 of 22
patients (13.6%) who attained stable disease or progressive
disease with IC had a tumor response with docetaxel. As
result, the final tumor response rate was slightly lower than
after four cycles of IC. Similar results were observed in the
first study reported by the Southwest Oncology Group
(SWOG), of sequential combination chemotherapy of gem-
citabine and carboplatin and then palcitaxel.28 The tumor
response rate after three cycles of gemcitabine and carbopla-
tin was 25%. Of the 25 patients who received sequential
paclitaxel, four (13%) attained a higher response, 13 (52%)
remained stable, and nine (36%) progressed. The second
SWOG study, which randomized patients to either gemcitab-
ine and carboplatin followed by paclitaxel or vinorelbine and
cisplatin followed by docetaxel, reported the same findings.29
Only 6% and 5%, respectively, of patients had improvements
in tumor response with sequential taxane therapy. In this
study, only patients with nonprogressive disease after three
TABLE 5. Change in Quality of Life (QOL) from Baseline during Irinotecan and Cisplatin (IC)
Administration
Cycle 1 (n  43)
Change (p)
Cycle 2 (n  35)
Change (p)
Cycle 3 (n  35)
Change (p)
Cycle 4 (n  35)
Change (p)
Physical 8.8 (0.01) 9.0 (0.02) 10.8 (0.02) 12.0 (0.01)
Role 11.2 (0.01) 9.0 (0.05) 10.5 (0.04) 10.0 (0.08)
Cognitive 9.4 (0.03) 6.0 (0.05) 7.6 (0.04) 7.6 (0.03)
Nausea 23.0 (0.0001) 9.3 (0.02) 26.2 (0.0001) 27.1 (0.0001)
Appetite 20.9 (0.0002) 20.4 (0.0003) 9.5 (0.09) 16.2 (0.008)
Diarrhea 8.5 (0.03) 9.3 (0.02) 4.8 (0.09) 9.5 (0.0057)
Hair loss 4.0 (0.20) 25.9 (0.0001) 30.5 (0.0001) 37.0 (0.0001)
Chest pain 4.6 (0.02) 1.0 (0.70) 5.7 (0.22) 6.0 (0.16)
Shoulder or arm pain 11.6 (0.001) 10.2 (0.001) 1.9 (0.66) 8.6 (0.05)
TABLE 6. Change of Quality of Life (QOL) from Last Cycle of Irinotecan and Cisplatin (IC)
during Docetaxel Administration
Cycle 1 (n  36)
Change (p)
Cycle 2 (n  36)
Change (p)
Cycle 3 (n  30)
Change (p)
Cycle 4 (n  28)
Change (p)
Physical 0.56 (0.8) 3.9 (0.26) 3.3 (0.36) 2.14 (0.58)
Role 0.9 (0.8) 0.5 (0.12) 1.6 (0.73) 1.2 (0.83)
Cognitive 1.4 (0.56) 9.8 (0.10) 2.8 (0.52) 2.9 (0.52)
Nausea 18.5 (0.0005) 21.3 (0.0001) 25.0 (0.0001) 25 (0.0001)
Diarrhea 7.4 (0.02) 9.3 (0.01) 6.7 (0.06) 8.3 (0.03)
Hair loss 18.0 (0.008) 9.3 (0.07) 16.7 (0.002) 4.8 (0.45)
Chest pain 0.9 (0.71) 3.7 (0.32) 4.4 (0.1) 5.9 (0.09)
Shoulder or arm pain 3.7 (0.37) 3.7 (0.32) 2.2 (0.57) 1.2 (0.76)
Sore mouth 10.1 (0.02) 10.1 (0.02) 7.7 (0.07) 7.14 (0.13)
Dyspnea 4.6 (0.14) 0.9 (0.74) 7.8 (0.02) 1.2 (0.71)
Hand or feet tingling 0.9 (0.76) 0.92 (0.81) 18.9 (0.001) 23.8 (0.0001)
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cycles of gemcitabine/ifosphamide/cisplatin (GIP) were ran-
domized. Tumor response rates for patients who received
three cycles of GIP and then three cycles of paclitaxel was
numerically lower than those for six cycles of GIP (36%
versus 44%; p 0.18). Furthermore, the high tumor response
rate reported in our study could be related to ethnicity. The
Japanese four-arm study comparing platinum-based doublet
reported a persistent higher response rate than did the West-
ern counterparts.5,21 Observation from multiple clinical trials
with sequential taxane after platinum-based combination che-
motherapy is contrary to the preclinical evidence of taxane
activity in platinum-resistant lung cancer.
This study resulted in progression free survival of 8.04
months (95% CI: 5.4–9.9 months), which seems to be an
improvement over IC alone from historic control.30 Using the
first day of docetaxel is used as a reference point, progres-
sion-free survival with sequential docetaxel was 6.1 months
(95% CI: 4.7–6.5 months). This also seems to be an improve-
ment to single-agent docetaxel as second-line therapy.13 Ad-
ministration of docetaxel sequentially after platinum-based
doublet therapy may potentially improve the progression-free
survival. Nevertheless, the study population included a high
proportion of patients with stage IIIB disease who would
have better treatment outcomes than would patients with
stage IV disease. The treatment duration of this study was
longer than for other studies; the patients received four cycles
of IC and then four cycles of docetaxel. In the two SWOG
studies of sequential chemotherapy, only three cycles of
platinum-based doublet therapy and three subsequent cycles
of a taxane were given; the median TTP ranged from 4.0 to
4.9 months. A recent randomized study comparing immediate
versus delayed docetaxel after induction chemotherapy of
gemcitabine and carboplatin reported significant prolongation
of progression-free survival (6.5 versus 2.8 months; p 
0.0001), favoring the sequential administration.31 The long
progression-free period observed in our study is in line with
their findings, although we cannot conclude with confidence
from our single-arm study.
Two randomized studies on maintenance therapy after
platinum-based doublet using the same agent did not show
improvement in overall survival.22,23 Brodowicz et al.23 ran-
domized patients to receive either gemcitabine or observation
immediately after tumor response or stable disease to first-
line therapy of gemcitabine and cisplatin, and they reported
overall survival of 13 months and 11 months, respectively
(p  0.19). Use of alternate cytotoxic drug immediately after
platinum-based doublet was shown to improve progression-
free survival, but the difference in overall survival was
statistically insignificant.31 We report an impressive median
survival of 14.6 months, but we are reluctant to conclude that
sequential therapy with either the same or an alternate agent
could prolong overall survival.
The 4-week schedule of IC was well tolerated. Bone
marrow suppression was mild, and only 6.5% of patients had
diarrhea of grade 2 or higher. By comparison, the sequential
administration of docetaxel was significantly more myelo-
toxic. The incidence of grade 3 to 4 neutropenia was higher
than any other studies of single-agent docetaxel as second-
line therapy.13,32 Seven patients (18.9%) experienced neutro-
penic fever during docetaxel administration, but none of these
fevers were fatal. Edelman et al.28 also reported a signifi-
cantly higher incidence of grade 3 and 4 neutropenia (70%)
with sequential combination chemotherapy of platinum-based
doublet therapy followed by docetaxel than with the sequen-
tial combination involving paclitaxel (47%). The combina-
tion of irinotecan and docetaxel was not particularly myelo-
toxic. This is similar to a previous study reporting the
incidence of grade 3 and 4 neutropenia to be 21.6%.33 Even
with the concurrent administration of a three-drug combina-
tion using irinotecan, paclitaxel, and carboplatin, the inci-
dence of grade 3 and 4 neutropenia was only 40%.34 There-
fore, the most likely explanation for the significant
neutropenia of docetaxel is the sequential administration
immediately after platinum-based doublet therapy.
Edelman et al.28 propose several reasons for sequential
combination chemotherapy not meeting the statistical criteria
for further study. These included the choice of agents that
were not truly non–cross resistant, large tumor burden in
stage IV disease, and modest efficacy of a taxane as a
second-line therapy. Our results are consistent with their
explanation. Edelman et al.28 used gemcitabine or vinorelbine
for their platinum-based doublet therapy, whereas we used
irinotecan. To this effect, all three nontaxane third-generation
cytotoxic drugs have failed to demonstrate non–cross resis-
tance with a taxane. We had a high proportion of patients
with stage IIIB disease, but we were not able to demonstrate
a definite improvement in treatment outcomes. Furthermore,
we have shown that the tumor response rate to sequential
administration of a taxane was not higher than the use of the
drug as a second-line therapy.
In conclusion, we have demonstrated sequential admin-
istration of irinotecan and cisplatin and then docetaxel to be
feasible and associated with prolonged progression-free sur-
vival, but we have not been able to demonstrate convincingly
that the sequential approach would improve the overall treat-
ment outcomes.
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